COMMENTARY: Review: Prophylactic use of granulocyte colony-stimulating factor reduces febrile neutropenia and short-term mortality in cancer

Frank, David A.
January 2008
ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p7
Academic Journal
The author comments on the study that evaluates the relationship of primary prophylactic use of granulocyte colony-stimulating factor (G-CSF) in reducing febrile neutropenia and early mortality of patient with cancer. He pointed out that the study recognizing that the patients with comorbid conditions might benefit from G-CSF even with less myelosuppressive chemotherapy. He suggests that the clinicians should consider that the pegylated G-CSF must be given to patient once per chemotherapy cycle.


Related Articles

  • Review: Prophylactic use of granulocyte colony-stimulating factor reduces febrile neutropenia and short-term mortality in cancer.  // ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p7 

    The article presents a clinical study that evaluates whether the primary prophylactic use of granulocyte colony-stimulating factor (G-CSF) reduces febrile neutropenia and early mortality in adult patients with cancer. The study showed that the use of G-CSF reduced febrile neutropenia and...

  • The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting. Tuffaha, Haitham W.; Treish, Imad M.; Zaru, Luna // Journal of Oncology Pharmacy Practice;Sep2008, Vol. 14 Issue 3, p131 

    Objectives. To conduct a drug utilization review (DUR) on the use of granulocyte colony-stimulating factor (G-CSF) and to study the effectiveness of this agent in preventing the incidence of febrile neutropenia (FN). Methods. Outpatients to whom G-CSF was dispensed were identified and their...

  • Pegfilgrastim for Chemotherapy-Induced Neutropenia. Bedell, Cindi // Clinical Journal of Oncology Nursing;Jan/Feb2003, Vol. 7 Issue 1, p55 

    Many chemotherapy regimens cause myelosuppression, which can result in febrile neutropenia and potentially lead to serious infections. The risk of neutropenia and its complications can be reduced with filgrastim, a granulocyteu colony-stimulating factor. Filgrastim is safe and effective, but it...

  • Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer? Skedgel, Chris; Rayson, Daniel; Younis, Tallal // Supportive Care in Cancer;Jan2016, Vol. 24 Issue 1, p387 

    Purpose: Febrile neutropenia (FN) during adjuvant chemotherapy is associated with morbidity, mortality risk, and substantial cost, and subsequent chemotherapy dose reductions may result in poorer outcomes. Patients at high risk of, or who develop FN, often receive prophylaxis with...

  • Pegfilgrastim the best choice for FN prevention in the UK.  // PharmacoEconomics & Outcomes News;10/31/2009, Issue 590, p3 

    The article discusses research on the use of pegfilgrastim for primary prophylaxis against febrile neutropenia (FN) in British women suffering from breast cancer. The article discusses the study "The Economic Value of Primary prophylaxis Using Pegfilgrastim Compared With Filgrastim in Patients...

  • Filgrastim.  // Reactions Weekly;8/3/2013, Issue 1464, p22 

    The article presents a case study about the development of tumour lysis-like syndrome in a 61-year-old man after receiving filgrastim for febrile neutropenia.

  • What is an ICER without QALYs gained?  // PharmacoEconomics & Outcomes News;Nov2013, Issue 691, p5 

    The article reports on the findings of a study in the Netherlands which suggest that a full six-cycle course of pegfilgrastim prophylaxis may be cost effective in patients with breast cancer at risk of febrile neutropenia.

  • Thiamazole.  // Reactions Weekly;6/14/2008, Issue 1206, p29 

    The article describes the case of a 42-year-old woman who developed febrile neutropenia while being treated with thiamazole for Grave's disease. It references a study by F. I. Jabr, published in the June 2008 issue of the "Southern Medical Journal." Examination revealed that the woman had mild,...

  • Is pegfilgrastim appropriate for the treatment of established febrile neutropenia? Stanford, Brad L.; Zondor, Stacey D.; Cobos, Everardo // Journal of Oncology Pharmacy Practice;Sep2003, Vol. 9 Issue 2/3, p113 

    Objective. To report a case where both pegfilgrastim and filgrastim were considered in the treatment of febrile neutropenia in a hospitalized patient and assess the most cost-effective option. Case summary. A 77-year-old white female was diagnosed with squamous cell carcinoma of the anus and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics